Sernova Biotherapeutics (HAM:PSH0) ROC %: -97.54% (As of Apr. 2026)

What is Sernova Biotherapeutics ROC %?

Sernova Biotherapeutics HAM:PSH0 -22.00% 28 ROC % is -97.54% as of Apr. 2026. GuruFocus rates HAM:PSH0 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sernova Biotherapeutics's annualized return on capital (ROC %) for the quarter that ended in Apr. 2026 was -97.54%.

As of today (2026-06-27), Sernova Biotherapeutics's WACC % is 4.27%. Sernova Biotherapeutics's ROC % is -116.03% (calculated using TTM income statement data). Sernova Biotherapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Sernova Biotherapeutics (HAM:PSH0) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sernova Biotherapeutics's WACC % is 4.27%. Sernova Biotherapeutics's ROC % is -116.03% (calculated using TTM income statement data). Sernova Biotherapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Sernova Biotherapeutics ROC % Related Terms

Sernova Biotherapeutics ROC % Historical Data

* Premium members only.

The historical data trend for Sernova Biotherapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics ROC % Chart

Sernova Biotherapeutics Annual Data

Trend

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Oct25

ROC %

Get a 7-Day Free Trial

-510.24

-1,595.31

-2,734.31

-2,512.37

-169.39

Sernova Biotherapeutics Quarterly Data
	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26	Apr26
ROC %	Get a 7-Day Free Trial															-611.32	-322.56	-90.38	-49.63	-97.54

28GF Score

Sernova Biotherapeutics Inc HAM:PSH0

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sernova Biotherapeutics ROC % Calculation

Sernova Biotherapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2025 is calculated as:

	ROC % (A: Oct. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Oct. 2024 )	+	Invested Capital (A: Oct. 2025 ))	/ count )
=	-9.226 * ( 1 - 0% )	/	( (0.773	+	10.12)	/ 2 )
=	-9.226	/	5.4465
=	-169.39 %

where

	Invested Capital		(A: Oct. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.023	-	13.289	-	( 4.012	-	max(0, 13.356	-	4.317	+	4.012	))
=	0.773

	Invested Capital		(A: Oct. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.469	-	5.256	-	( 0.163	-	max(0, 15.228	-	0.321	+	0.163	))
=	10.12

Sernova Biotherapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Apr. 2026 is calculated as:

	ROC % (Q: Apr. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jan. 2026 )	+	Invested Capital (Q: Apr. 2026 ))	/ count )
=	-5.712 * ( 1 - 0% )	/	( (10.324	+	1.388)	/ 2 )
=	-5.712	/	5.856
=	-97.54 %

where

	Invested Capital		(Q: Jan. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.626	-	5.602	-	( 0.356	-	max(0, 15.78	-	0.48	+	0.356	))
=	10.324

	Invested Capital		(Q: Apr. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.954	-	5.421	-	( 0.655	-	max(0, 6.803	-	0.948	+	0.655	))
=	1.388

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -97.54% mean?

Sernova Biotherapeutics (HAM:PSH0) has a ROC % of -97.54% as of Apr. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Sernova Biotherapeutics and its competitors.

Is Sernova Biotherapeutics' ROC % too high?

Sernova Biotherapeutics' current ROC % is -97.54%. Overall, Sernova Biotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Sernova Biotherapeutics' ROC % compare to VRTX and REGN?

Sernova Biotherapeutics' ROC % of -97.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Sernova Biotherapeutics and its competitors. Sernova Biotherapeutics's current ROC % is -97.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sernova Biotherapeutics stock overvalued right now?

Sernova Biotherapeutics (HAM:PSH0) has a current ROC % of -97.54%. The current ROC % is -97.54%. Sernova Biotherapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Sernova Biotherapeutics (HAM:PSH0), the current ROC % is -97.54% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sernova Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:METX XCNQ:TELI XCNQ:DTC TSXV:MIR TSXV:NRX TSX:MBX XCNQ:QNTM TSX:BCT TSX:MDNA TSXV:SHRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges SEOVF:USA PSH0:Germany SVA:Canada

Address RPO Central Parkway, PO Box 29592, Mississauga, ON, CAN, L5A 4H2

Website https://www.sernova.com

Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.

28GF Score

Get the complete analysis for HAM:PSH0

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05

Price

View HAM:PSH0 Analysis

See ROC % data for all stocks →